ACCESSWIRE
25 Nov 2020, 00:13 GMT+10
SAN FRANCISCO, CA / ACCESSWIRE / November 24, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company'), a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, today announced the release of a podcast interview conducted by Jaguar's founder, president, and CEO, Lisa Conte, with The Wall Street Resource.
To listen to the interview, go to https://thewallstreetresource.com/webcasts
About The Wall Street Resource
The Wall Street Resource.com is a paid publishing platform for microcap discovery and due diligence, and a resource for webcast interviews of CEOs and executives. For more information, please visit www.thewallstreetresource.com.
About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commmercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.
For more information about Jaguar, please visit https://jaguar.health. For more information about Napo, visit www.napopharma.com.
About Mytesi®
Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Forward-Looking Statements
Certain statements in this press release constitute 'forward-looking statements.' In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
Get a daily dose of St Louis Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to St Louis Star.
More InformationSince September, the devastation wrought by the COVID-19 pandemic has deepened, infecting close to 100 million people, costing more than ...
The Russian vessel tapped to finish the controversial Nord Stream 2 gas pipeline has begun work in Danish waters just ...
President Joe Biden has issued an executive order that overturns a ban on transgender people serving in the U.S. military.In ...
NEW DELHI, India - India and China have agreed to push for an early disengagement of the frontline troops in ...
PanARMENIAN.Net - There is some evidence that a new coronavirus variant first identified in southeast England carries a higher risk ...
AMSTERDAM, Netherlands - A Canadian man, one of the world's most wanted fugitives, has been arrested by the Central Unit ...
NEW YORK, New York - U.S. stocks were out of favour on Tuesday with the main indices drifting lower.At the ...
NEW DELHI, India - After clashes between protestors and police in several parts of Delhi, farmers on Tuesday, the Samyukta ...
SYDNEY, NSW, Australia - Stocks in Asia lost ground on Tuesday.The Australian market missed the damage as markets were closed ...
WASHINGTON, DC, January 26 (ANI) - The U.S. Senate has confirmed Janet Yellen to be the next Secretary of the ...
NEW YORK, New York - Wall Street got the wobbles on Monday after a sell-off in Europe and the UK. ...
Washington [US], January 25 (ANI): Potterheads have a reason to rejoice as a new 'Harry Potter' television series is currently ...